Hydrogen sulfide and its enzyme's role in protecting the Alzheimer's brain

Neuroprotective actions of cystathionine g-lyase through gasotransmitter hydrogen sulfide signaling

NIH-funded research Johns Hopkins University · NIH-11308305

Researchers are exploring whether boosting the brain's hydrogen sulfide signaling can protect brain cells in people with Alzheimer's disease.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionJohns Hopkins University NIH-funded
Lab location1 site (Baltimore, United States)
Project IDNIH-11308305 on NIH RePORTER

What this research studies

This project looks at how the brain makes hydrogen sulfide (a small signaling gas) and how that process, controlled by enzymes like cystathionine γ-lyase (CSE), helps protect neurons in Alzheimer's disease. Scientists will use laboratory experiments and Alzheimer's mouse models to map the signaling steps and study a protein change called sulfhydration that may keep cells healthy. They will compare enzyme activity and related biomarkers between healthy and diseased models to identify molecular targets for drugs. Findings are intended to guide early-stage treatment development but will not immediately change clinical care.

Who could benefit from this research

Good fit: Ideal candidates for future related trials would be people with Alzheimer's disease or mild cognitive impairment interested in treatments aimed at protecting neurons.

Not a fit: People without Alzheimer's, or patients seeking immediate symptom relief, are unlikely to benefit directly from this lab-focused project.

Why it matters

Potential benefit: If successful, this work could point to new treatments that protect brain cells and slow Alzheimer's progression.

How similar studies have performed: Previous studies have shown altered hydrogen sulfide signaling in Alzheimer's, but turning those findings into effective therapies remains largely unproven.

Where this research is happening

Baltimore, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer disease dementia
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.